» Articles » PMID: 1999624

Coronary Vasodilation is Impaired in Both Hypertrophied and Nonhypertrophied Myocardium of Patients with Hypertrophic Cardiomyopathy: a Study with Nitrogen-13 Ammonia and Positron Emission Tomography

Overview
Date 1991 Mar 15
PMID 1999624
Citations 82
Authors
Affiliations
Soon will be listed here.
Abstract

To assess regional coronary reserve in hypertrophic cardiomyopathy, regional myocardial blood flow was measured in 23 patients with hypertrophic cardiomyopathy and 12 control subjects by means of nitrogen-13 ammonia and dynamic positron emission tomography. In patients with hypertrophic cardiomyopathy at baseline study, regional myocardial blood flow was 1.14 +/- 0.43 ml/min per g in the hypertrophied (20 +/- 3 mm) interventricular septum and 0.90 +/- 0.35 ml/min per g (p less than 0.05 versus septal flow) in the nonhypertrophied (10 +/- 2 mm) left ventricular free wall. These were not statistically different from the corresponding values in control subjects (1.04 +/- 0.25 and 0.91 +/- 0.21 ml/min per g, respectively, p = NS). After pharmacologically induced coronary vasodilation (dipyridamole, 0.56 mg/kg intravenously over 4 min), regional myocardial blood flow in patients with hypertrophic cardiomyopathy increased significantly less than in control subjects both in the septum (1.63 +/- 0.58 versus 2.99 +/- 1.06 ml/min per g, p less than 0.001) and in the free wall (1.47 +/- 0.58 versus 2.44 +/- 0.82 ml/min per g, p less than 0.001). In addition, patients with hypertrophic cardiomyopathy who had a history of chest pain had more pronounced impairment of coronary vasodilator reserve than did those without a history of chest pain. After dipyridamole, coronary resistance in the septum decreased by 38% in patients without a history of chest pain, but decreased by only 14% in those with such a history (p less than 0.05). Coronary resistance in the free wall decreased by 45% in patients without and by 27% in those with a history of chest pain (p = 0.06).(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Coronary Microvascular Dysfunction and Vasospastic Angina-Pathophysiology, Diagnosis and Management Strategies.

Abramik J, Mariathas M, Felekos I J Clin Med. 2025; 14(4).

PMID: 40004660 PMC: 11856034. DOI: 10.3390/jcm14041128.


Tailored Therapies for Cardiogenic Shock in Hypertrophic Cardiomyopathy: Navigating Emerging Strategies.

Zakynthinos G, Gialamas I, Tsolaki V, Pantelidis P, Goliopoulou A, Gounaridi M J Cardiovasc Dev Dis. 2024; 11(12).

PMID: 39728291 PMC: 11678468. DOI: 10.3390/jcdd11120401.


The spectrum and systemic associations of microvascular dysfunction in the heart and other organs.

Emfietzoglou M, Terentes-Printzios D, Kotronias R, Marin F, Montalto C, De Maria G Nat Cardiovasc Res. 2024; 1(4):298-311.

PMID: 39196132 DOI: 10.1038/s44161-022-00045-5.


Exercise in Hypertrophic Cardiomyopathy: Recent Conceptual Changes and Recommendations for Pre-Exercise Tests.

Seo J, Choi E, Rim S Rev Cardiovasc Med. 2024; 24(6):166.

PMID: 39077517 PMC: 11264120. DOI: 10.31083/j.rcm2406166.


Chemokine Fractalkine and Non-Obstructive Coronary Artery Disease-Is There a Link?.

Stangret A, Sadowski K, Jablonski K, Kochman J, Opolski G, Grabowski M Int J Mol Sci. 2024; 25(7).

PMID: 38612695 PMC: 11012077. DOI: 10.3390/ijms25073885.